+ bone marrow cells; 10 4 events were analyzed for each sample.
TO THE EDITOR
Chronic myeloid leukemia (CML) is a neoplastic disorder arising from a stem cell with multilineage differentiation capabilities. The typical translocation t(9;22) has been identified in different lineages using cytometric and molecular methods. In these studies, all the maturation stages of granulopoiesis, erythropoiesis and megakaryocytopoiesis showed the t(9;22). 1 B cell involvement in the neoplastic process is more controversial despite the development of frequent lymphoid blast crisis in the terminal phases of the disease. Clonality search has been hampered by the low number of lymphocytes present in the blood and bone marrow of CML patients. 2 Torlakovic et al 3 found the Ph chromosome in CD20 lymphocytes in two patients with CML using tricolor immunophenotyping/FISH. CD3 lymphocytes were negative in all the patients tested. Haferlach Flow cytometry is an interesting approach to the study of the lymphoid compartment in CML. Lucio et al 4 have analyzed 38 bone marrow samples from normal adult volunteers using the combination CD10 CD20 CD19 and have defined three major CD19 B cell maturation stages: CD20 − CD19 + CD10 + is the most immature subpopulation which in adults represents 0.12 ± 0.12% of the total BM nucleated cells; CD20 + CD19 + CD10 + is the intermediate subpopulation which accounts for 0.8 ± 0.59%; and CD20
is the most mature subpopulation (2.22 ± 0.99) of total BM nucleated cells.
Residual leukemic cells in patients with B cell lineage ALL alter the normal B cell differentiation pathway. These abnormalities include an increase in the percentage of immature B cells (CD34
− , an altered differentiation pattern with a blockade and the presence of B cells outside the normal pathway. [4] [5] [6] Recently, we analyzed the B cell differentiation in two cases of Phchromosome positive CML (p210, b 2 a 2 ) (Figure 1) . One patient had a myeloid blast crisis and the other had an early myeloid accelerated phase with 15% of promyelo-promonocytes and 5% of myeloid blasts in the bone marrow. We used the monoclonal antibody combinations and the criteria of normal B cell differentiation described in earlier studies by Ciudad et al 6 and Lucio et al. 4 In both cases we detected an increase in the immature B cells (CD19 
× 14 mg/m 2 Idarubicin during induction: results of a pilot study in children with AML

TO THE EDITOR
Idarubicin (IDR) is one of the most effective, but also toxic drugs in the treatment of AML. A finding, which was supported by several trials in adults, comparing induction regimens with daunorubicin (DNR) vs IDR which resulted in higher complete remission (CR) rates in the IDR group. 1 The standard dose applied in children and adults is 8-12 mg/m 2 during induction. To further improve results we increased the IDR dose from 12 mg/m 2 as given in study AML-BFM 93 during induction (AIE = Ara-C, idarubicin, etoposide) to 14 mg/m 2 in a pilot study. Seventeen children and adolescents (16 with de novo AML, one with secondary AML) from 11 hospitals (Dü sseldorf, Freiburg, Hamburg, Hannover, Homburg/Saar, Münster, Ulm, Tü bingen, Mü nchen, Wien, Jena) were included (pilot group A). Informed consent from the children or parents was obtained. Outcome and toxicities were compared with the other 447 patients of study AML-BFM 93, enrolled until April 1998, who were treated with 12 mg/m 2 /day × 3 days IDR (group B) or 2 × 30 mg/m 2 /day × 3 days DNR (group C) during induction. Further treatment consisted of a 6-week consolidation therapy with seven different drugs in standard risk patients (M1/M2 with Auer rods and M4eo and a blast cell reduction on day 15р5%, M3 all patients), 2 whereas high risk patients (all others) received an additional block high-dose Ara-C plus mitoxantrone (HAM). Then, all patients were treated with one block of high-dose Ara-C plus VP-16, cranial irradiation with 18 Gy (standard dose in children у3 years) and maintenance therapy for a total duration of 18 months. tion treatment on later treatment complications. Documentation of toxicity data according to the NCI common toxicity criteria was extended in the patients of the pilot group and in a subset of protocol patients (control group B1 = 32 patients treated with 3 × 12 mg/m 2 IDR) and control group C1 (33 patients treated with 6 × 30 mg/m 2 DNR).
CR was defined according to the CALGB criteria. Patients not having achieved CR until the end of intensification treatment were allocated to nonresponders. Follow-up was as of February 1999.
Patient characteristics of group A are shown in Table 1 . Differences in FAB distribution, gender, leukocyte count and bone marrow blasts on day 15 between group A and groups B and C (data not shown) were not significant. However, slightly more patients of group A had unfavorable criteria, eg FAB type MO (3/17 patients = 18% vs 22/447 = 5%, P (Fisher test) = 0.09), or unfavorable immunology (biphenotypical features with expression of cyCD3, 2 patients), unfavorable cytogenetics (t(11;19) or complex aberrations, 4 patients) and hyperleukocytosis (2 patients, one extreme).
Overall results of group A are presented in Table 2 in comparison with groups B and C. Blast cell reduction on day 15 in the BM was significantly better in children treated with IDR (12 and 14 mg/m 2 ) compared to patients treated with DNR (P ( 2 ) = 0.035). Sixteen of 17 group A patients (94%) achieved remission, which was not significantly different to the other groups. Relapse rate was low in group A and B, (cumulative incidence 20%, s.e. 12% and 24%, s.e. 4%) but also low in group C (21%, s.e. 4%). However, follow-up is still short.
Overall, induction treatment in group A patients was feasible, but quite toxic, due to severe aplasia (in median 25 days, range 12-66 days) after starting induction to neutrophil recovery Ͼ500/l. However, not significantly longer compared to group B1 and C1 with 25.0 (12-47) and 23.0 (13-60) days, respectively (Table 3) . Duration of thrombopenia Ͻ20 000/l in group A patients was 21.0 (10-66) days compared to 19.0 (13-56) days in group C1 patients, P (U-test) = 0.08.
Four patients suffered from severe (grade 3/4) sepsis and pneumonia. Another six patients showed fever of unknown origin (FUO) for 4-12 days. Severe mucositis (grade 3/4) occurred in four patients.
